Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2013

01-07-2013 | Original Article

Relationships between hepatitis B infection status and liver dysfunction after chemotherapy of lung cancer patients in mainland China

Authors: Huang Ruofan, Zhan Qiong, Zhou Xinli, Chu Zhaohui, Jiang Jingwei, Liang Xiaohua

Published in: Supportive Care in Cancer | Issue 7/2013

Login to get access

Abstract

Purpose

A preliminary analysis on the risk factors of liver dysfunction was made after the investigation of hepatitis B prevalence and chemotherapy-related hepatic dysfunction occurrence for patients with lung cancer.

Patients and methods

Consecutively diagnosed 950 lung cancer patients treated in Huashan Hospital, Fudan University from 1999 to 2009 were enrolled in the study. We investigated hepatitis B (HB) prevalence and analyzed chemotherapy-related hepatic dysfunction occurrence and its influencing factors. Liver dysfunction was considered when alanine transaminase, aspartate aminotransferase, and serum bilirubin levels exceeded at least 1.25-fold of normal levels, and HB statuses were categorized into diagnosed HB, previous HB infection, HB immunity, and no HB infection.

Results

Among the 950 lung cancer patients, 632 accepted the HB serum marker tests: 8.4 % (53/632) were HB surface antigen positive, and 37.2 % (235/632) were HB core antibody positive. A number of 281 patients received liver function follow-up examinations after they underwent a total of 774 chemotherapy courses, and 34 liver dysfunctions were detected. A logistic regression analysis showed that younger age at diagnosis (≤60 years; P = 0.029) and abnormal liver function before chemotherapy (P = 0.000) were the risk factors for liver dysfunctions after chemotherapy, but HB status had no influence.

Conclusions

The screening rates for serum HB marker and HB prevalence in patients with lung cancer were high in mainland China. Lung cancer patients with abnormal liver function before chemotherapy and in younger ages had higher risks for liver dysfunctions after chemotherapies, whereas HB status before the first chemotherapy is not an independent impact factor for post-treatment liver dysfunctions.
Literature
1.
2.
Kao JH (2008) Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol 2:553–562PubMedCrossRef
3.
Liang X, Bi S, Yang W, Wang L, Cui G, Cui F et al (2009) Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 27:6550–6557PubMedCrossRef
4.
Lau GK (2008) Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2:152–162PubMedCrossRef
5.
Cainelli F, Vento S (2010) Time for universal HIV and HBV screening for patients with cancer. Lancet Oncol 11:916–918PubMedCrossRef
6.
Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME (2011) Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 8:e32–e39CrossRef
7.
Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ (2008) Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 8:115PubMedCrossRef
8.
Zhang HY, Liu ZG, Zhang Z, Gong HY (2010) Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy. Zhonghua Zhong Liu Za Zhi 32:459–462PubMed
Metadata
Title
Relationships between hepatitis B infection status and liver dysfunction after chemotherapy of lung cancer patients in mainland China
Authors
Huang Ruofan
Zhan Qiong
Zhou Xinli
Chu Zhaohui
Jiang Jingwei
Liang Xiaohua
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1738-2

Other articles of this Issue 7/2013

Supportive Care in Cancer 7/2013 Go to the issue

Original Article

Toward clinical care guidelines for supporting rehabilitative vaginal dilator use with women recovering from cervical cancer

Original Article

Impact of palliative care consultative service on disease awareness for patients with terminal cancer

Original Article

Associations between voice quality and swallowing function in patients treated for oral or oropharyngeal cancer

Original Article

Medication use in breast cancer survivors compared to midlife women

Original Article

Return to work after treatment for primary breast cancer over a 6-year period: results from a prospective study comparing patients with the general population

Original Article

Spiritual well-being in lung cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits